膀胱癌组织肿瘤细胞及肿瘤相关免疫细胞中PD-L1的表达及其临床意义

Abstract
Figure/Table
References (21)
Related Citation (8)

Download: PDF (429 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To detect expressions of programmed cell death ligand 1 (PD-L1) in tumor cells (TC) and tumor-infiltrating immune cells (IC) of bladder cancer and investigate its clinical significance. Methods The paraffin-embedded specimens of 87 patients with bladder cancer undergoing surgery in Renmin Hospital of Wuhan University from January 2018 to December were collected. The expressions of PD-L1 in TC and IC were detected by immunohistochemical SP263 staining. Results The positive rate of PD-L1 expression in bladder cancer IC was higher than that in TC, and the difference was highly statistically significant (P ＜ 0.01), while there was a positive correlation between them (P ＜ 0.01). The positive expressions of PD-L1 in TC of bladder cancer were related to age, gender and pathological grade, and the differences were statistically significant (P ＜ 0.05). While the positive expressions in IC were associated with age, pathological grade, myometrial invasion, and the differences were statistically significant (P ＜ 0.05). Conclusion The abnormal up-regulation of PD-L1 expression in TC and IC of bladder cancer tissues may be closely related to the occurrence and development of bladder cancer.

Key words： Bladder cancer Programmed cell death ligand 1 Tumor cell Tumor-infiltrating immune cell

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yanze WANG Lei CHEN Zhiyuan LIU Xiuheng

Cite this article:

LI Yanze WANG Lei CHEN Zhiyuan LIU Xiuheng. Expression of PD-L1 in tumor cells and tumor-associated immune cells of bladder cancer and its clinical significance[J]. 中国医药导报, 2019, 16(27): 77-80.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I27/77

[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA：A Cancer Journal for Clinicians，2016，66（2）：115-132.
[2] Kim J. Immune checkpoint blockade therapy for bladder cancer treatment [J]. Investig Clin Urol，2016，57（Suppl 1）：S98-S105.
[3] Galsky MD，Hahn NM，Rosenberg J，et al. Treatment of Patients with Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy [J]. J Clin Oncol，2011，29（17）：2432-2438.
[4] 黄健.免疫检查点抑制剂对膀胱癌患者的治疗作用及不良反应管理[J].中华泌尿外科杂志，2017，38（10）：721-724.
[5] Ghasemzadeh A，Bivalacqua TJ，Hahn NM，et al. New Strategies in Bladder Cancer：A Second Coming for Immunotherapy [J]. Clin Cancer Res，2015，22（4）：793-801.
[6] Postow MA，Callahan MK，Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy [J]. J Clin Oncol，2015， 33（17）：1974-1982.
[7] Boorjian SA，Sheinin Y，Crispen PL，et al. T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma：Clinicopathologic Correlations and Association with Survival [J]. Clin Cancer Res，2008，14（15）：4800-4808.
[8] Paul S，Marietta S，Nicola L，et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay [J]. Diagn Pathol，2018，13（1）：47.
[9] Munari E，Rossi G，Zamboni G，et al. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs：An Interclone Evaluation by Differently Trained Pathologists [J]. Am J Surg Pathol，2018，42（10）：1384-1389.
[10] Mu CY，Huang JA，Chen Y，et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation [J]. Med Oncol，2011，28（3）：682-688.
[11] Ning YM，Suzman D，Maher VE，et al. FDA Approval Summary：Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy [J]. Oncologist，2017， 22（6）：743-749.
[12] Sharma P，Callahan MK，Bono P，et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma（CheckMate 032）：a multicentre，open-label，two-stage，multi-arm，phase 1/2 trial [J]. Lancet Oncol，2016，17（11）：1590-1598.
[13] Massard C，Gordon MS，Sharma S，et al. Safety and efficacy of Durvalumab （MEDI4736），an anti-programmed cell death Ligand-1 immune checkpoint inhibitor，in patients with advanced Urothelial bladder cancer [J]. J Clin Oncol，2016，34（26）：3119-3125.
[14] Bellmunt J，de Wit R，Vaughn DJ，et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma [J]. N Engl J Med，2017， 376（11）：1015-1026.
[15] Powles T，Eder JP，Fine GD，et al. MPDL3280A （anti-PD-L1） treatment leads to clinical activity in metastatic bladder cancer [J]. Nature，2014，515（7528）：558-562.
[16] Sundararajan S，Vogelzang NJ. Anti-PD-1 and PD-L1 therapy for bladder cancer：what is on the horizon? [J]. Future Oncol，2015，11（16）：2299-2306.
[17] Alsaab HO，Sau S，Alzhrani R，et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy：mechanism，combinations，and clinical outcome [J]. Front Pharmacol，2017，8：561.
[18] Sun Z，Fourcade J，Pagliano O，et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells [J]. Cancer Res，2015，75（8）：1635-1644.
[19] Pyo JS，Kang G，Kim JY. Prognostic role of PD-L1 in malignant solid tumors：a meta-analysis [J]. Int J Biol Markers，2017，32（1）：e68-e74.
[20] Xylinas E，Robinson BD，Kluth LA，et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder [J]. Eur J Surg Onc，2014，40（1）：121-127.
[21] Tumeh PC，Harview CL，Yearley JH，et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance [J]. Nature，2014，515（7528）：568-571.